<DOC>
	<DOCNO>NCT01842594</DOCNO>
	<brief_summary>Determine objective response rate sarcoma patient treat hydroxychloroquine sirolimus .</brief_summary>
	<brief_title>A Phase II Trial Combined Hydroxychloroquine Sirolimus Soft Tissue Sarcoma</brief_title>
	<detailed_description>This study evaluate daily morning single dose hydroxychloroquine /sirolimus combine therapy sarcoma patient . Study arm treat hydroxychloroquine 400 mg /sirolimus 2mg gd 8-wk therapy . Patients discontinue study 8-wk observation period . Patients must meet follow inclusion criterion eligible enrollment study . TREATMENT PLAN : 1 . Both hydroxychloroquine 200 mg/tab sirolimus 1 mg/tab pill take 2 tablet orally every day . Treatment divide time period call cycle . Each treatment cycle 28 day . The exception 28 day cycle participant start take pill first time . When hydroxychloroquine sirolimus begin , first cycle 28 day begin . 2 . There several test procedure perform specific time period protocol treatment . These include : blood work , performance status assessment , question medical history medication , tumor assessment PET/CT MRI , eye exam . 3 . Dose modification criterion : Participants may continue receive study treatment long experience grade 1 2 side effect . The treatment drug 50 % reduction dose grade 3 toxicity ; discontinue treatment ( off-study ) grade 4 toxicity disease progression treatment .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Hydroxychloroquine</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Patients Soft tissue sarcoma ( include high grade low grade soft tissue sarcoma、osteogenic sarcoma follow 4 recurrent benign tumor may aggressive clinical course initial surgical treatment : lymphangioleiomyomatosis、angiomyolipoma、giant cell tumor、phylloid tumor ) refractory least first line full course standard chemotherapy , relapse standard chemotherapy , standard therapy available refuse chemotherapy Patients must &gt; /= 21 year . Patients must &gt; /= 4 week beyond treatment cytotoxic chemotherapy regimen , therapeutic radiation , major surgery . Patients may receive palliative localize radiation immediately treatment provide radiation deliver site disease treat protocol . For biologic/targeted agent patient must &gt; /= 5 halflives &gt; /= 3 week form last dose ( whichever come first ) . Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; /= 2 Patients must certain organ marrow function resave define : White blood cell ( WBC_ &gt; /= 3,000/mL ; platelet &gt; /=100,000/mL ; creatinine &lt; /= 2 X Upper Limit Normal ( ULN ) ; total bilirubin &lt; /= 2.0 ; Alanine Aminotransferase ( ALT ; SGPT ) &lt; /= 5 X ULN ; Exception patient liver metastasis : total bilirubin &lt; /= 3 x ULN ; ALT ( SGPT ) &lt; /= 8 X ULN ; cholesterol &lt; /= 350 mg/dL ; triglyceride &lt; /= 400 mg/dL ( sirolimus hydroxychloroquine ) . Patients must able understand willing sign write informed consent document . Uncontrolled intercurrent illness , include , limited , uncontrolled infection , uncontrolled asthma , need hemodialysis , need ventilatory support . Pregnant lactating woman . History hypersensitivity sirolimus . History hypersensitivity hydroxychloroquine Patients unwilling unable sign inform consent document .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Sarcoma , Hydroxychloroquine , Sirolimus , PET</keyword>
</DOC>